Sign In
Buy TBPH
$15.92
+0.340 (+2.18%)
At Close: Jun 03, 2026
Theravance Biopharma to Report Second Quarter 2021 Financial Results on August 3, 2021
06:00am, Tuesday, 20'th Jul 2021
DUBLIN, Ireland, July 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization
Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares
10:56pm, Thursday, 24'th Jun 2021
DUBLIN, June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on the discovery, development and c
Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares
04:33pm, Thursday, 24'th Jun 2021
DUBLIN, June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on the discovery, development and co
Theravance (TBPH) COVID-19 Therapy Fails in Mid-Stage Study
10:31am, Tuesday, 22'nd Jun 2021
Theravance's (TBPH) JAK inhibitor candidate, nezulcitinib, fails to achieve statistically significant improvement in the number of respiratory failure-free days in hospitalized COVID-19 patients with
Theravance Biopharma Stock Drops After Nezulcitinib Disappoints In COVID-19 Study
07:37am, Monday, 21'st Jun 2021
Theravance Biopharma Inc (NASDAQ: TBPH) has announced top-line results from its Phase 2 study evaluating nezulcitinib for hospitalized patients with confirmed COVID-19 associated acute lung injury
DUBLIN and SOUTH SAN FRANCISCO, Calif., June 21, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmaceutical company prima
20 Short Ideas With Super-Weak Momentum
10:39am, Monday, 31'st May 2021
Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since
Theravance Biopharma to Participate in an Upcoming Investor Conference
06:00am, Thursday, 06'th May 2021
DUBLIN, May 6, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-s
Theravance (TBPH) Q1 Earnings Lag Estimates, Pipeline on Track
11:39am, Wednesday, 05'th May 2021
Theravance's (TBPH) loss narrows in the first quarter of 2021 while revenues decline year over year.
Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q1 2021 Results - Earnings Call Transcript
10:25pm, Tuesday, 04'th May 2021
Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q1 2021 Results - Earnings Call Transcript
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
06:02pm, Tuesday, 04'th May 2021
Theravance Bio (TBPH) delivered earnings and revenue surprises of -18.10% and -18.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma: Q1 Earnings Insights
04:51pm, Tuesday, 04'th May 2021
Shares of Theravance Biopharma (NASDAQ:TBPH) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 8.77% over the past year to ($1.24)
Theravance Biopharma to Report First Quarter 2021 Financial Results on May 4, 2021
06:00am, Tuesday, 20'th Apr 2021
DUBLIN, April 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of orga
Theravance (TBPH) Q4 Earnings Top Estimates, Revenues In Line
11:23am, Wednesday, 24'th Feb 2021
Theravance's (TBPH) loss narrows in the fourth quarter of 2020 while revenues meet the consensus estimate.
Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q4 2020 Results - Earnings Call Transcript
09:31pm, Tuesday, 23'rd Feb 2021
Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q4 2020 Results - Earnings Call Transcript
